January 6, 2011

CALIFON, NJ, Jan. 6 /PRNewswire/ – Hospital specialty pharmaceutical company
PediatRx Inc. (“PediatRx”) began trading under the symbol OTCBB:PEDX
following a merger with its wholly-owned subsidiary, effective December
28, 2010

The initial PediatRx therapeutic area of focus is cancer and associated
conditions/supportive care.

PediatRx has acquired GRANISOL(TM), the only FDA-approved liquid oral
granisetron, used for the prevention of nausea and vomiting (emesis)
associated with initial and repeat courses of chemotherapy or
radiation. GRANISOL is available in an orange-flavored, ready-to-use
liquid oral solution and offers an alternative to patients who may not
be able, or not wish, to take tablets, IVs or other forms of
anti-emesis therapy during cancer treatment. Following the acquisition
of GRANISOL, PediatRx established manufacturing and distribution
agreements with key partners to make GRANISOL available at key oncology
centers and retail pharmacies in the USA.

PediatRx also intends to acquire and/or license, and  become the sole
marketer in the United States, of other FDA-approved, branded
prescription drugs as well as reformulate certain compounds as more
appropriate forms. 

PediatRx has a category-expert management team of experienced
entrepreneurs with a proven track record of success in big pharma,
specialty pharma and start ups. This includes Dr. Cameron Durrant in the role of President, Chief Executive Officer
and Director, David Tousley as Chief Financial Officer and Director,
and Jorge Rodriguez as Vice President and Chief Commercial
Officer. Details on management’s backgrounds can be found on the
company website: www.pediatrx.com.


Granisetron is indicated for the prevention of:

  • Nausea and vomiting associated with initial and repeat courses of
    emetogenic cancer therapy, including high-dose cisplatin.

  • Nausea and vomiting associated with radiation, including total body
    irradiation and fractionated abdominal radiation.

Selected Safety Information

  • Granisetron is contraindicated in patients with known hypersensitivity
    to the drug or any of its components.   

  • QT prolongation has been reported with granisetron. Use of Granisol Oral
    Solution in patients concurrently treated with drugs known to prolong
    the QT interval and/or are arrhythmogenic may result in clinical

  • This drug should be used during pregnancy only if clearly needed.   

  • It is not known whether granisetron is excreted in human milk. Because
    many drugs are excreted in human milk, caution should be exercised when
    granisetron is administered to a nursing woman.

  • Efficacy and safety were maintained with increasing age in the geriatric

  • Safety and effectiveness in pediatric patients have not been

  • The most common side effects observed with administration of granisetron
    were headache, asthenia, somnolence, diarrhea and constipation.

About PediatRx Inc.

PediatRx Inc. (www.pediatrx.com) is a unique hospital specialty pharmaceutical company and the first to
focus on children suffering from serious conditions requiring
hospitalization and hospital care. PediatRx trades on the OTCBB under
the ticker symbol PEDX.

PediatRx Inc. is a corporation formerly known as Striker Energy Corp.
(SKRY.OB), which changed its name by a vertical merger with its
wholly-owned subsidiary, PediatRx Inc.

This press release contains forward-looking statements. Forward-looking
statements are projections of events, revenues, income, future
economic, research, development, reformulation, product performance or
management’s plans and objectives for future operations. In some cases
you can identify forward-looking statements by the use of terminology
such as “may”, “should”, “anticipates”, “believes”, “expects”,
“intends”, “forecasts”, “plans”, “future”, “strategy”, or words of
similar meaning. Forward-looking statements in this press release
include those concerning PediatRx’s intention to acquire and/or
license, and  become the sole marketer in the United States, of other
FDA-approved, branded prescription drugs as well as reformulate certain
compounds as more appropriate forms. While these forward-looking
statements and any assumptions upon which they are based are made in
good faith and reflect current judgment regarding the direction of the
business operations of PediatRx, actual results will almost always
vary, sometimes materially, from any estimates, predictions,
projections, assumptions or other future performance suggested in this
press release. These statements are predictions and involve known and
unknown risks, uncertainties and other factors, including the risk that
PediatRx cannot execute its business plan for lack of capital or other
resources, distribution, partnering or licensing/acquisition
opportunities, as well as the risks described in the periodic
disclosure documents filed on EDGAR by PediatRx, copies of which are
also available on the company’s website. Any of these risks could cause
PediatRx or its industry’s actual results, levels of activity,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements in this press
release. Except as required by applicable law, including the securities
laws of the United States, PediatRx does not intend to update any of
the forward-looking statements to conform these statements to actual

PD 25 (01/11)

CONTACT: <p>PediatRx Inc.<br/> Research & Business Development<br/> Email: <a href=”mailto:info@pediatrx.com”>info@pediatrx.com</a></p> <p>Shareholder & Media Relations<br/> +1 908 975 0753<br/> Email: <a href=”mailto:ir@pediatrx.com”>ir@pediatrx.com</a></p>

SOURCE PediatRx Inc.

Source: newswire

comments powered by Disqus